William Blair Has Positive Forecast for WST Q3 Earnings

Key Points

• William Blair has raised its Q3 2025 earnings estimate for West Pharmaceutical Services from $1.60 to $1.68 per share, with a full-year estimate of $6.62 per share.
• West Pharmaceutical Services plans to increase its quarterly dividend to $0.22 per share, reflecting confidence in its financial position.
• The company reported Q2 earnings exceeding analysts' expectations, with revenue of $766.50 million, surpassing the consensus estimate of $725.11 million.

West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) - Research analysts at William Blair lifted their Q3 2025 EPS estimates for shares of West Pharmaceutical Services in a report released on Thursday, July 24th. William Blair analyst M. Larew now expects that the medical instruments supplier will post earnings of $1.68 per share for the quarter, up from their prior forecast of $1.60. The consensus estimate for West Pharmaceutical Services' current full-year earnings is $6.62 per share. William Blair also issued estimates for West Pharmaceutical Services' Q4 2025 earnings at $1.83 EPS, FY2025 earnings at $6.81 EPS, Q1 2026 earnings at $1.63 EPS, Q2 2026 earnings at $1.98 EPS, Q3 2026 earnings at $1.93 EPS, Q4 2026 earnings at $2.11 EPS and FY2026 earnings at $7.67 EPS.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.51 by $0.33. The firm had revenue of $766.50 million for the quarter, compared to the consensus estimate of $725.11 million. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The business's revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.52 EPS.

Other equities analysts also recently issued reports about the stock. Wall Street Zen raised shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Barclays started coverage on shares of West Pharmaceutical Services in a report on Tuesday, June 24th. They set an "equal weight" rating and a $245.00 price objective on the stock. Citigroup reaffirmed a "buy" rating on shares of West Pharmaceutical Services in a report on Thursday, May 22nd. Stephens raised shares of West Pharmaceutical Services to a "strong-buy" rating in a report on Monday, April 21st. Finally, UBS Group upped their price objective on shares of West Pharmaceutical Services from $285.00 to $320.00 and gave the company a "buy" rating in a report on Friday, July 25th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $320.71.

West Pharmaceutical Services Stock Performance

Shares of NYSE:WST traded down $5.07 during midday trading on Monday, reaching $244.15. The company had a trading volume of 101,646 shares, compared to its average volume of 871,441. The company's 50 day moving average price is $222.92 and its 200 day moving average price is $237.52. The company has a current ratio of 2.78, a quick ratio of 2.08 and a debt-to-equity ratio of 0.07. The stock has a market cap of $17.56 billion, a P/E ratio of 36.57, a P/E/G ratio of 4.40 and a beta of 1.09. West Pharmaceutical Services has a 52-week low of $187.43 and a 52-week high of $352.33.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $222,000. LPL Financial LLC boosted its stake in shares of West Pharmaceutical Services by 25.4% during the fourth quarter. LPL Financial LLC now owns 65,757 shares of the medical instruments supplier's stock valued at $21,539,000 after purchasing an additional 13,301 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of West Pharmaceutical Services by 3.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 128,678 shares of the medical instruments supplier's stock valued at $43,179,000 after purchasing an additional 4,699 shares during the period. UniSuper Management Pty Ltd boosted its stake in shares of West Pharmaceutical Services by 18.2% during the fourth quarter. UniSuper Management Pty Ltd now owns 8,159 shares of the medical instruments supplier's stock valued at $2,673,000 after purchasing an additional 1,259 shares during the period. Finally, Norges Bank purchased a new stake in West Pharmaceutical Services in the fourth quarter worth $290,604,000. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 19th. Investors of record on Wednesday, November 12th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.36%. This is a boost from West Pharmaceutical Services's previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, November 12th. West Pharmaceutical Services's dividend payout ratio is 12.57%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.